Inhibikase Therapeutics (IKT) investor relations material

Executive summary

• Lead product candidate IKT-001 for Pulmonary Arterial Hypertension (PAH) is in a global Phase 3 trial, with 26 country approvals and 43 clinical sites activated as of June 30, 2026.

• Orphan Drug Designation for IKT-001 was granted by the FDA in July 2026, providing development incentives, tax credits, user fee exemptions, and potential market exclusivity.

• Recent data presented at a major conference highlighted IKT-001's improved gastrointestinal side-effect profile and efficacy markers compared to imatinib.

• $50 million was raised in July 2026 through a share sale, primarily to RA Capital, strengthening liquidity.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $159.0 million at June 30, 2026.

• Net loss for Q2 2026 was $19.6 million ($0.11 per share), compared to $9.9 million ($0.11 per share) in Q2 2025; net loss for the first half of 2026 was $36.0 million ($0.21 per share), up from $23.6 million ($0.26 per share) year-over-year.

• Research and development expenses rose to $13.4 million in Q2 2026 from $5.3 million in Q2 2025, primarily due to increased PAH program costs.

• Selling, general, and administrative expenses increased to $7.7 million in Q2 2026 from $5.9 million in Q2 2025, mainly from higher stock-based compensation and professional fees.

• Other income increased 59% year-over-year for Q2, driven by higher interest income.

Outlook and guidance

• Existing cash and securities are expected to fund operations for at least the next twelve months and through topline data readout in Part B of the Phase 3 IMPROVE-PAH study, assuming timely exercise of outstanding warrants.

• Anticipates continued increases in R&D expenses as clinical programs advance.

• Additional funding may be required for future operations and commercialization efforts.

• Ongoing regulatory submissions and approvals are anticipated to further expand the Phase 3 trial footprint.